8-K
filed April 30, 2026, 7:59 PM ET
ticker LGND
CIK 0000886163
other material
confidence high
sentiment negative
materiality 0.70
Ligand terminates TR-Beta license with Viking over alleged material breach; Viking disputes
LIGAND PHARMACEUTICALS INC
- Termination of TR-Beta Program (including VK2809 and VK0214) effective May 4, 2026.
- Ligand asserts Viking materially breached obligation to use commercially reasonable efforts.
- Viking disputes termination; Ligand intends to vigorously enforce its termination rights.
- Upon termination, licenses revert to Ligand; Viking must grant non-exclusive worldwide royalty-bearing license at low single digits royalty rate.
Machine-readable event card
- schema_version
- secwatch.filing_event.v1
- accession
- 0000886163-26-000027
- form_type
- 8-K
- ticker
- LGND
- cik
- 0000886163
- company_name
- LIGAND PHARMACEUTICALS INC
- filed_at
- 2026-04-30T23:59:59+00:00
- discovered_at
- 2026-05-14T18:02:33.873167+00:00
- generated_at
- 2026-05-15T01:25:42.471895+00:00
- sec_items
- ["1.02"]
- event_type
- other_material
- sentiment
- negative
- materiality_score
- 0.7
- calibrated_materiality_score
- 0.7
- confidence
- high
- secwatch_canonical_url
- https://secwatch.observer/filing/0000886163-26-000027
- json_url
- https://secwatch.observer/filing/0000886163-26-000027.json
- markdown_url
- https://secwatch.observer/filing/0000886163-26-000027.md
- text_url
- https://secwatch.observer/filing/0000886163-26-000027.txt
- edgar_index_url
- https://www.sec.gov/Archives/edgar/data/886163/000088616326000027/0000886163-26-000027-index.htm
- edgar_primary_document_url
- https://www.sec.gov/Archives/edgar/data/886163/000088616326000027/lgnd-20260424.htm
- generated_by_model
- deepseek-v4-flash:cloud@v2
- review_status
- machine_generated
- human_reviewed
- false
- corrected
- false
- correction_note
- null
- correction_timestamp
- null
- superseded_by
- null
Comparable filings
BBDC
Barings BDC receives $67M cash from adviser, enters new $11M credit support for Sierra legacy investments
Barings BDC, Inc.
June 1, 2026, 4:15 PM ET
other_material
Items 1.01, 1.02, 9.01
same fact type: material_agreement
same SEC item: 1.02
same event type: other_material
similar materiality
This filing
On April 24, 2026, Ligand Pharmaceuticals Incorporated (the “Company”) delivered written notice to Viking Therapeutics, Inc. (“Viking”) of termination of the TR-Beta Program (the “Termination Notice”) under that certain Master License Agreement, dated May 21, 2014, by and among the Company, Metabasis Therapeutics, Inc. and Viking, as amended by the First Amendment dated September 6, 2014, the Second Amendment dated April 8, 2015, and the Waiver, Consent and Third Amendment dated March 21, 2016 (the “License Agreement”).
Comparable filing
Barings BDC, Inc. (the “Company”) and Barings LLC (the “Adviser”) entered into a new Credit Support Agreement (the “New CSA”). The New CSA provides similar credit support as previously provided under the Prior CSA for the remaining unrealized investments in two portfolio companies previously covered by the Prior CSA in an amount equal to the $10,994,928 fair value of such investments as of May 29, 2026 (the “Remaining Obligation”).
Filing page
SEC filing
SERV
Serve Robotics ends $150M ATM sales agreement, reports pro forma Q1 net loss of $51M from Diligent acquisition
Serve Robotics Inc. /DE/
May 11, 2026, 7:59 PM ET
other_material
Items 1.02, 8.01, 9.01
same fact type: material_agreement
same SEC item: 1.02
same event type: other_material
similar materiality
This filing
On April 24, 2026, Ligand Pharmaceuticals Incorporated (the “Company”) delivered written notice to Viking Therapeutics, Inc. (“Viking”) of termination of the TR-Beta Program (the “Termination Notice”) under that certain Master License Agreement, dated May 21, 2014, by and among the Company, Metabasis Therapeutics, Inc. and Viking, as amended by the First Amendment dated September 6, 2014, the Second Amendment dated April 8, 2015, and the Waiver, Consent and Third Amendment dated March 21, 2016 (the “License Agreement”).
Comparable filing
On May 7, 2026, Serve Robotics Inc. (the “Company”) and each of Cantor Fitzgerald & Co., Wedbush Securities Inc., Northland Securities, Inc., Ladenburg Thalmann & Co. Inc. and Seaport Global Securities LLC (collectively, the “Agents”) agreed to terminate the Controlled Equity Offering SM Agreement, dated as of March 6, 2025 (the “Prior Sales Agreement”).
Filing page
SEC filing
BBIO
BridgeBio Pharma establishes $500M at-the-market equity offering program
BridgeBio Pharma, Inc.
May 8, 2026, 7:59 PM ET
other_material
Items 1.01, 1.02, 9.01
same fact type: material_agreement
same SEC item: 1.02
same event type: other_material
similar materiality
This filing
On April 24, 2026, Ligand Pharmaceuticals Incorporated (the “Company”) delivered written notice to Viking Therapeutics, Inc. (“Viking”) of termination of the TR-Beta Program (the “Termination Notice”) under that certain Master License Agreement, dated May 21, 2014, by and among the Company, Metabasis Therapeutics, Inc. and Viking, as amended by the First Amendment dated September 6, 2014, the Second Amendment dated April 8, 2015, and the Waiver, Consent and Third Amendment dated March 21, 2016 (the “License Agreement”).
Comparable filing
On May 7, 2026, in connection with entering into the Agreement, the Company agreed with Goldman Sachs and Leerink Partners (formerly known as SVB Securities LLC), to terminate that certain Equity Distribution Agreement, dated May 4, 2023, by and among the Company, Goldman Sachs and Leerink Partners, effective as of May 7, 2026.
Filing page
SEC filing
AVAI
AVAI Bio and Ainnova Tech mutually terminate JV agreement as of May 7, 2026
AVAI BIO, INC.
May 8, 2026, 7:59 PM ET
other_material
Items 1.02, 9.01
same fact type: material_agreement
same SEC item: 1.02
same event type: other_material
similar materiality
This filing
On April 24, 2026, Ligand Pharmaceuticals Incorporated (the “Company”) delivered written notice to Viking Therapeutics, Inc. (“Viking”) of termination of the TR-Beta Program (the “Termination Notice”) under that certain Master License Agreement, dated May 21, 2014, by and among the Company, Metabasis Therapeutics, Inc. and Viking, as amended by the First Amendment dated September 6, 2014, the Second Amendment dated April 8, 2015, and the Waiver, Consent and Third Amendment dated March 21, 2016 (the “License Agreement”).
Comparable filing
On May 7, 2026, Avai Bio, Inc., formerly known as Avant Technologies Inc. (the “Company” or “AVAI”), and Ainnova Tech Inc. (“Ainnova” or “AINN”) entered into a Mutual Termination Agreement (the “Termination Agreement”) to terminate, by mutual consent, the Joint Venture and License Agreement dated November 8, 2024 (effective as of November 11, 2024) (the “License Agreement”).
Filing page
SEC filing
BTBD
BT Brands terminates Aero Velocity merger; registration statement not declared effective by April 30, 2026
BT Brands, Inc.
May 7, 2026, 7:59 PM ET
other_material
Items 1.02, 8.01, 7.01, 9.01
same fact type: material_agreement
same SEC item: 1.02
same event type: other_material
similar materiality
This filing
On April 24, 2026, Ligand Pharmaceuticals Incorporated (the “Company”) delivered written notice to Viking Therapeutics, Inc. (“Viking”) of termination of the TR-Beta Program (the “Termination Notice”) under that certain Master License Agreement, dated May 21, 2014, by and among the Company, Metabasis Therapeutics, Inc. and Viking, as amended by the First Amendment dated September 6, 2014, the Second Amendment dated April 8, 2015, and the Waiver, Consent and Third Amendment dated March 21, 2016 (the “License Agreement”).
Comparable filing
On May 1, 2026, the Company delivered written notice to Aero terminating the Merger Agreement pursuant to Section 7.1(b) thereof.
Filing page
SEC filing
HWH
HWH enters $10M PIPE with warrants at $0.50/share; terminates Hapi Metaverse acquisition
HWH International Inc.
May 7, 2026, 7:59 PM ET
other_material
Items 1.01, 1.02, 5.02, 9.01
same fact type: material_agreement
same SEC item: 1.02
same event type: other_material
similar materiality
This filing
On April 24, 2026, Ligand Pharmaceuticals Incorporated (the “Company”) delivered written notice to Viking Therapeutics, Inc. (“Viking”) of termination of the TR-Beta Program (the “Termination Notice”) under that certain Master License Agreement, dated May 21, 2014, by and among the Company, Metabasis Therapeutics, Inc. and Viking, as amended by the First Amendment dated September 6, 2014, the Second Amendment dated April 8, 2015, and the Waiver, Consent and Third Amendment dated March 21, 2016 (the “License Agreement”).
Comparable filing
On May 5, 2026, HWH International Inc., a Nevada corporation (the “Company”) entered into a term sheet (the “Term Sheet”) with Smart Dynamics Technology Limited, a company incorporated in the British Virgin Islands (the “Investor”), pursuant to which the Company has agreed to sell to the Investor, for an aggregate purchase price of $10,000,000
Filing page
SEC filing
STRT
Strattec's JV replacement credit agreement releases company from guaranty obligations
STRATTEC SECURITY CORP
April 30, 2026, 7:59 PM ET
other_material
Items 1.02
same fact type: material_agreement
same SEC item: 1.02
same event type: other_material
similar materiality
This filing
On April 24, 2026, Ligand Pharmaceuticals Incorporated (the “Company”) delivered written notice to Viking Therapeutics, Inc. (“Viking”) of termination of the TR-Beta Program (the “Termination Notice”) under that certain Master License Agreement, dated May 21, 2014, by and among the Company, Metabasis Therapeutics, Inc. and Viking, as amended by the First Amendment dated September 6, 2014, the Second Amendment dated April 8, 2015, and the Waiver, Consent and Third Amendment dated March 21, 2016 (the “License Agreement”).
Comparable filing
Effective as of April 30, 2026, ADAC-STRATTEC, LLC (“ADAC-STRATTEC”), a majority owned joint venture subsidiary of Strattec Security Corporation (the “Company”), entered into an Amended and Restated Credit Agreement with BMO Bank N.A. (the “New JV Credit Agreement”) that replaced ADAC-STRATTEC’s existing credit agreement, dated June 28, 2012, with BMO Bank N.A.
Filing page
SEC filing
PMHS
ForHumanity terminates exclusive marketing deal with Polomar; Polomar disputes claims
Polomar Health Services, Inc.
April 29, 2026, 7:59 PM ET
other_material
Items 1.02, 9.01
same fact type: material_agreement
same SEC item: 1.02
same event type: other_material
similar materiality
This filing
On April 24, 2026, Ligand Pharmaceuticals Incorporated (the “Company”) delivered written notice to Viking Therapeutics, Inc. (“Viking”) of termination of the TR-Beta Program (the “Termination Notice”) under that certain Master License Agreement, dated May 21, 2014, by and among the Company, Metabasis Therapeutics, Inc. and Viking, as amended by the First Amendment dated September 6, 2014, the Second Amendment dated April 8, 2015, and the Waiver, Consent and Third Amendment dated March 21, 2016 (the “License Agreement”).
Comparable filing
On April 23, 2026, the Company received a written notice (the “Notice”) that ForHumanity intends to terminate and rescind the ForHumanity Agreement, among other matters.
Filing page
SEC filing
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.